Botulinum toxin type-A in the prevention of migraine

A double-blind controlled trial

Alexander Vo, Roberto Satori, Bahman Jabbari, Jody Green, William D S Killgore, Robert Labutta, William W. Campbell

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Introduction: Migraine is a frequent medical complaint. In military populations, migraine can be detrimental to productivity and troop readiness, and can be disqualifying for service in some military duty specialties. This study assessed the effectiveness of botulinum neurotoxin type-A (BTX-A) in reducing the frequency of migraines in known migraineurs. Methods: There were 32 subjects (control = 17, test n = 15) who completed the assessment battery at baseline and monthly for 3 mo. Adult subjects with migraine headaches occurring more than 5 times/month were recruited and randomized to receive placebo saline injection vs. BTX-A. The primary efficacy parameter was the average frequency of headache days for 3 mo. Secondary outcome measures were severity of attacks and quality of life. Results: Quadratic trends were noted for headache severity (F (2,29) = 14.1, p = 0.001) and headache indexes (F (2,29) = 4.5, p = 0.042) for both groups, suggesting changes in severity of head pain and overall intensity of headaches experienced over time; however, results were not significant for headache frequency and severity between groups. Paired t-tests of the headache index scores for the control group revealed a significant increase from the first to the third follow-up periods (t = -2.58, p = 0.020). Such a trend was not observed for the BTX-A group. Both groups, however, reported similarly low to moderate quality of life as a result of their migraines. Conclusions: This controlled trial failed to demonstrate efficacy of BTX-A in reducing the frequency of migraine headaches. The pattern headache index in the botox group, however, suggested a protective effect for botox against the headache severity.

Original languageEnglish (US)
JournalAviation Space and Environmental Medicine
Volume78
Issue number5 II
StatePublished - May 2007

Fingerprint

Type A Botulinum Toxins
Migraine Disorders
Headache
Productivity
Quality of Life
Placebos
Outcome Assessment (Health Care)
Control Groups
Injections

Keywords

  • Botulinum toxin type-A
  • Headache
  • Migraine
  • Quality of life

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pollution
  • Medicine(all)

Cite this

Vo, A., Satori, R., Jabbari, B., Green, J., Killgore, W. D. S., Labutta, R., & Campbell, W. W. (2007). Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial. Aviation Space and Environmental Medicine, 78(5 II).

Botulinum toxin type-A in the prevention of migraine : A double-blind controlled trial. / Vo, Alexander; Satori, Roberto; Jabbari, Bahman; Green, Jody; Killgore, William D S; Labutta, Robert; Campbell, William W.

In: Aviation Space and Environmental Medicine, Vol. 78, No. 5 II, 05.2007.

Research output: Contribution to journalArticle

Vo, A, Satori, R, Jabbari, B, Green, J, Killgore, WDS, Labutta, R & Campbell, WW 2007, 'Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial', Aviation Space and Environmental Medicine, vol. 78, no. 5 II.
Vo, Alexander ; Satori, Roberto ; Jabbari, Bahman ; Green, Jody ; Killgore, William D S ; Labutta, Robert ; Campbell, William W. / Botulinum toxin type-A in the prevention of migraine : A double-blind controlled trial. In: Aviation Space and Environmental Medicine. 2007 ; Vol. 78, No. 5 II.
@article{9966fcba71e34d1c98b73d1ab5e0f7ea,
title = "Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial",
abstract = "Introduction: Migraine is a frequent medical complaint. In military populations, migraine can be detrimental to productivity and troop readiness, and can be disqualifying for service in some military duty specialties. This study assessed the effectiveness of botulinum neurotoxin type-A (BTX-A) in reducing the frequency of migraines in known migraineurs. Methods: There were 32 subjects (control = 17, test n = 15) who completed the assessment battery at baseline and monthly for 3 mo. Adult subjects with migraine headaches occurring more than 5 times/month were recruited and randomized to receive placebo saline injection vs. BTX-A. The primary efficacy parameter was the average frequency of headache days for 3 mo. Secondary outcome measures were severity of attacks and quality of life. Results: Quadratic trends were noted for headache severity (F (2,29) = 14.1, p = 0.001) and headache indexes (F (2,29) = 4.5, p = 0.042) for both groups, suggesting changes in severity of head pain and overall intensity of headaches experienced over time; however, results were not significant for headache frequency and severity between groups. Paired t-tests of the headache index scores for the control group revealed a significant increase from the first to the third follow-up periods (t = -2.58, p = 0.020). Such a trend was not observed for the BTX-A group. Both groups, however, reported similarly low to moderate quality of life as a result of their migraines. Conclusions: This controlled trial failed to demonstrate efficacy of BTX-A in reducing the frequency of migraine headaches. The pattern headache index in the botox group, however, suggested a protective effect for botox against the headache severity.",
keywords = "Botulinum toxin type-A, Headache, Migraine, Quality of life",
author = "Alexander Vo and Roberto Satori and Bahman Jabbari and Jody Green and Killgore, {William D S} and Robert Labutta and Campbell, {William W.}",
year = "2007",
month = "5",
language = "English (US)",
volume = "78",
journal = "Aerospace medicine and human performance",
issn = "2375-6314",
publisher = "Aerospace Medical Association",
number = "5 II",

}

TY - JOUR

T1 - Botulinum toxin type-A in the prevention of migraine

T2 - A double-blind controlled trial

AU - Vo, Alexander

AU - Satori, Roberto

AU - Jabbari, Bahman

AU - Green, Jody

AU - Killgore, William D S

AU - Labutta, Robert

AU - Campbell, William W.

PY - 2007/5

Y1 - 2007/5

N2 - Introduction: Migraine is a frequent medical complaint. In military populations, migraine can be detrimental to productivity and troop readiness, and can be disqualifying for service in some military duty specialties. This study assessed the effectiveness of botulinum neurotoxin type-A (BTX-A) in reducing the frequency of migraines in known migraineurs. Methods: There were 32 subjects (control = 17, test n = 15) who completed the assessment battery at baseline and monthly for 3 mo. Adult subjects with migraine headaches occurring more than 5 times/month were recruited and randomized to receive placebo saline injection vs. BTX-A. The primary efficacy parameter was the average frequency of headache days for 3 mo. Secondary outcome measures were severity of attacks and quality of life. Results: Quadratic trends were noted for headache severity (F (2,29) = 14.1, p = 0.001) and headache indexes (F (2,29) = 4.5, p = 0.042) for both groups, suggesting changes in severity of head pain and overall intensity of headaches experienced over time; however, results were not significant for headache frequency and severity between groups. Paired t-tests of the headache index scores for the control group revealed a significant increase from the first to the third follow-up periods (t = -2.58, p = 0.020). Such a trend was not observed for the BTX-A group. Both groups, however, reported similarly low to moderate quality of life as a result of their migraines. Conclusions: This controlled trial failed to demonstrate efficacy of BTX-A in reducing the frequency of migraine headaches. The pattern headache index in the botox group, however, suggested a protective effect for botox against the headache severity.

AB - Introduction: Migraine is a frequent medical complaint. In military populations, migraine can be detrimental to productivity and troop readiness, and can be disqualifying for service in some military duty specialties. This study assessed the effectiveness of botulinum neurotoxin type-A (BTX-A) in reducing the frequency of migraines in known migraineurs. Methods: There were 32 subjects (control = 17, test n = 15) who completed the assessment battery at baseline and monthly for 3 mo. Adult subjects with migraine headaches occurring more than 5 times/month were recruited and randomized to receive placebo saline injection vs. BTX-A. The primary efficacy parameter was the average frequency of headache days for 3 mo. Secondary outcome measures were severity of attacks and quality of life. Results: Quadratic trends were noted for headache severity (F (2,29) = 14.1, p = 0.001) and headache indexes (F (2,29) = 4.5, p = 0.042) for both groups, suggesting changes in severity of head pain and overall intensity of headaches experienced over time; however, results were not significant for headache frequency and severity between groups. Paired t-tests of the headache index scores for the control group revealed a significant increase from the first to the third follow-up periods (t = -2.58, p = 0.020). Such a trend was not observed for the BTX-A group. Both groups, however, reported similarly low to moderate quality of life as a result of their migraines. Conclusions: This controlled trial failed to demonstrate efficacy of BTX-A in reducing the frequency of migraine headaches. The pattern headache index in the botox group, however, suggested a protective effect for botox against the headache severity.

KW - Botulinum toxin type-A

KW - Headache

KW - Migraine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=34248185152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248185152&partnerID=8YFLogxK

M3 - Article

VL - 78

JO - Aerospace medicine and human performance

JF - Aerospace medicine and human performance

SN - 2375-6314

IS - 5 II

ER -